Stock Track | Relay Therapeutics Plummets 13.33% as Missed Revenue Expectations and Losses Weigh on Shares

Stock Track

Feb 27, 2025

Relay Therapeutics (RLAY) stock plummeted 13.33% during the pre-market trading session on Thursday, following the company's disappointing earnings report for the fourth quarter of 2024.

While Relay Therapeutics reported better-than-expected earnings per share (EPS) of -$0.45, beating analyst estimates of -$0.56, the company failed to generate any revenue during the quarter. This missed analysts' expectations of $6.08 million in revenue, weighing heavily on the stock's performance.

Additionally, Relay Therapeutics reported a quarterly loss of $76 million, further contributing to the stock's decline. As a biotech company without any current products on the market, missed revenue expectations and continued losses can be seen as concerning by investors, as it raises questions about the company's ability to generate profitable growth in the future.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1185137319"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1185137319\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1185137319?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 22:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185137319","market":"us","top_or_hot":-1,"title":"Stock Track | Relay Therapeutics Plummets 13.33% as Missed Revenue Expectations and Losses Weigh on Shares","media":"Stock Track","content":"<p>Relay Therapeutics (RLAY) stock plummeted 13.33% during the pre-market trading session on Thursday, following the company's disappointing earnings report for the fourth quarter of 2024.</p>\n\n<p>While Relay Therapeutics reported better-than-expected earnings per share (EPS) of -$0.45, beating analyst estimates of -$0.56, the company failed to generate any revenue during the quarter. This missed analysts' expectations of $6.08 million in revenue, weighing heavily on the stock's performance.</p>\n\n<p>Additionally, Relay Therapeutics reported a quarterly loss of $76 million, further contributing to the stock's decline. As a biotech company without any current products on the market, missed revenue expectations and continued losses can be seen as concerning by investors, as it raises questions about the company's ability to generate profitable growth in the future.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Relay Therapeutics Plummets 13.33% as Missed Revenue Expectations and Losses Weigh on Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Relay Therapeutics Plummets 13.33% as Missed Revenue Expectations and Losses Weigh on Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-27 22:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Relay Therapeutics (RLAY) stock plummeted 13.33% during the pre-market trading session on Thursday, following the company's disappointing earnings report for the fourth quarter of 2024.</p>\n\n<p>While Relay Therapeutics reported better-than-expected earnings per share (EPS) of -$0.45, beating analyst estimates of -$0.56, the company failed to generate any revenue during the quarter. This missed analysts' expectations of $6.08 million in revenue, weighing heavily on the stock's performance.</p>\n\n<p>Additionally, Relay Therapeutics reported a quarterly loss of $76 million, further contributing to the stock's decline. As a biotech company without any current products on the market, missed revenue expectations and continued losses can be seen as concerning by investors, as it raises questions about the company's ability to generate profitable growth in the future.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RLAY","symbol_name":"Relay Therapeutics","start_time":0,"source_url":"","article_id":"1185137319","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185137319","pubTimestamp":1740667200,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Relay Therapeutics  stock plummeted 13.33% during the pre-market trading session on Thursday, following the company's disappointing earnings report for the fourth quarter of 2024.While Relay Therapeutics reported better-than-expected earnings per share  of -$0.45, beating analyst estimates of -$0.56, the company failed to generate any revenue during the quarter. This missed analysts' expectations of $6.08 million in revenue, weighing heavily on the stock's performance.Additionally, Relay Therape","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RLAY":"Relay Therapeutics"},"translate_title":"由于收入未达预期和亏损令股价承压，Relay Therapeutics股价暴跌13.33%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RLAY":1},"content_text":"Relay Therapeutics (RLAY) stock plummeted 13.33% during the pre-market trading session on Thursday, following the company's disappointing earnings report for the fourth quarter of 2024.\nWhile Relay Therapeutics reported better-than-expected earnings per share (EPS) of -$0.45, beating analyst estimates of -$0.56, the company failed to generate any revenue during the quarter. This missed analysts' expectations of $6.08 million in revenue, weighing heavily on the stock's performance.\nAdditionally, Relay Therapeutics reported a quarterly loss of $76 million, further contributing to the stock's decline. As a biotech company without any current products on the market, missed revenue expectations and continued losses can be seen as concerning by investors, as it raises questions about the company's ability to generate profitable growth in the future.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}